China's first new crown inactivated vaccine enters phase Ⅱ clinical trial

  The reporter learned from the SASAC today that the new inactivated coronavirus vaccine developed by Sinopharm Group's Wuhan Institute of Biological Products officially entered Phase II clinical research. As of April 23, China Bio-New Crown Inactivated Vaccine has completed the vaccination of 96 people in the first three age groups in the first phase, and the current vaccination situation has shown good safety. Ongoing safety observations are still ongoing. (Guo Miao, the reporter of Central Broadcasting Station)